Changes in Eye Tissue May Enable Early Detection of Brain Diseases
|
By LabMedica International staff writers Posted on 11 Oct 2016 |

Image: An experiment examining retina tissue for mHtt deposition in GFAP-ir astrocytes in R6/2 mouse model of Huntington’s Disease. Green: glial fibrillary acidic protein (GFAP); Red: mutant huntingtin protein (mHtt). (A) A low magnification picture illustrates GFAP-ir astrocytes and mHtt deposits from the retinal wholemount of 12-week-old R6/2 (Huntington’s disease model) mouse. Scale bar = 50 µm. (B) A detailed confocal analysis of GFAP positivity, mHtt immunoreactivity, and DAPI counterstain (blue) revealed no colocalization of GFAP and mHtt. Scale bar = 20 µm (Image courtesy of PLoS One).
Research with mouse models has shown that at least some diseases of the central nervous system (CNS) manifest as pathological changes in the retina of the eye and that these changes may be detected earlier than brain changes. The findings suggest that eye examination could be used for minimally invasive screening for these diseases.
Retina tissue can be considered an integral part of the central nervous system (CNS). During fetal development, it matures from part of the brain and its innervation closely resembles that of the brain. Retinal structure and function can be readily examined with noninvasive or minimally invasive methods, whereas direct brain examination has numerous limitations. If, at least for some brain diseases, the health status of the brain could be indirectly assessed through the eyes, diagnostic screening could become more efficient.
In his PhD project at the University of Eastern Finland at Kuopio (Kuopio, Finland), Dr. Henri Leinonen and colleagues investigated functional abnormalities of the retina using mouse models of human CNS diseases. Electroretinography (ERG) and visual evoked potentials (VEP) were chosen as research techniques, since similar methodology can be applied in both laboratory animals and humans. ERG can precisely track the function of retina using corneal or skin electrodes, whereas VEP measures the function of visual cortex.
These methods were used to test different attributes of vision in 3 distinct genetically engineered mouse models of human CNS diseases. Also, basic life science methods were used to test the correlation between functional abnormalities and the anatomical status of the retina.
Day and color vision -associated retinal dysfunction was found in a mouse model of Huntington´s disease (HD) while the mouse was presymptomatic. Retinal structure remained relatively normal, even in an advanced disease state, although aggregation of toxic mutated huntingtin-protein was widespread in the diseased mouse retina. Although the retinopathy in mice is exaggerated compared to human HD patients, the finding is partly in line with patient data showing impaired color vision but no clear-cut anatomical retinopathy.
In a mouse model of Alzheimer´s disease (AD), the researchers observed abnormality in night vision -associated retinal function. Specifically, rod-mediated inner retinal responses to dim light flashes were faster in diseased mice than in their wild-type controls. The observation may be explained by impaired cholinergic neurotransmission that is also partly causative for the deterioration of memory in AD.
In a mouse model of late infantile neuronal ceroid lipofuscinosis (NCL), a pediatric neurological disease, the researchers described retinal degenerative changes that mimic the characteristic pathology of age-related macular degeneration (AMD). These included impaired function of retinal pigment epithelium and subsequent blindness due to photoreceptor atrophy and death. It has been postulated that the retinal degeneration in human patients progresses similarly.
Adding to the growing body of evidence, the results showed that functional changes of the retina occur in mouse models of three human CNS diseases whose phenotype, age of onset, and pathological mechanism clearly differ from each other. Visual impairment was the fastest progressive symptom in two models tested.
The findings support the idea of eye examinations as potential screening tools for CNS diseases. Development of efficient, safe, and economic screening is imperative since the diagnosis of these diseases is often obtained only in the advanced disease state, when as such satisfactory remedies are poorly effective. Since eye and vision research can be conducted noninvasively, advancement of trials from the preclinical to the clinical phase could be relatively fast.
Dr. Leinonen’s doctoral dissertation, entitled “Electrophysiology of visual pathways as a screening tool for neurodegenerative diseases: evidence from mouse disease models”, is available for download. The findings were published in PLoS One, the Journal of Alzheimer’s Disease, and most recently in the journal Human Molecular Genetics.
Related Links:
University of Eastern Finland
Retina tissue can be considered an integral part of the central nervous system (CNS). During fetal development, it matures from part of the brain and its innervation closely resembles that of the brain. Retinal structure and function can be readily examined with noninvasive or minimally invasive methods, whereas direct brain examination has numerous limitations. If, at least for some brain diseases, the health status of the brain could be indirectly assessed through the eyes, diagnostic screening could become more efficient.
In his PhD project at the University of Eastern Finland at Kuopio (Kuopio, Finland), Dr. Henri Leinonen and colleagues investigated functional abnormalities of the retina using mouse models of human CNS diseases. Electroretinography (ERG) and visual evoked potentials (VEP) were chosen as research techniques, since similar methodology can be applied in both laboratory animals and humans. ERG can precisely track the function of retina using corneal or skin electrodes, whereas VEP measures the function of visual cortex.
These methods were used to test different attributes of vision in 3 distinct genetically engineered mouse models of human CNS diseases. Also, basic life science methods were used to test the correlation between functional abnormalities and the anatomical status of the retina.
Day and color vision -associated retinal dysfunction was found in a mouse model of Huntington´s disease (HD) while the mouse was presymptomatic. Retinal structure remained relatively normal, even in an advanced disease state, although aggregation of toxic mutated huntingtin-protein was widespread in the diseased mouse retina. Although the retinopathy in mice is exaggerated compared to human HD patients, the finding is partly in line with patient data showing impaired color vision but no clear-cut anatomical retinopathy.
In a mouse model of Alzheimer´s disease (AD), the researchers observed abnormality in night vision -associated retinal function. Specifically, rod-mediated inner retinal responses to dim light flashes were faster in diseased mice than in their wild-type controls. The observation may be explained by impaired cholinergic neurotransmission that is also partly causative for the deterioration of memory in AD.
In a mouse model of late infantile neuronal ceroid lipofuscinosis (NCL), a pediatric neurological disease, the researchers described retinal degenerative changes that mimic the characteristic pathology of age-related macular degeneration (AMD). These included impaired function of retinal pigment epithelium and subsequent blindness due to photoreceptor atrophy and death. It has been postulated that the retinal degeneration in human patients progresses similarly.
Adding to the growing body of evidence, the results showed that functional changes of the retina occur in mouse models of three human CNS diseases whose phenotype, age of onset, and pathological mechanism clearly differ from each other. Visual impairment was the fastest progressive symptom in two models tested.
The findings support the idea of eye examinations as potential screening tools for CNS diseases. Development of efficient, safe, and economic screening is imperative since the diagnosis of these diseases is often obtained only in the advanced disease state, when as such satisfactory remedies are poorly effective. Since eye and vision research can be conducted noninvasively, advancement of trials from the preclinical to the clinical phase could be relatively fast.
Dr. Leinonen’s doctoral dissertation, entitled “Electrophysiology of visual pathways as a screening tool for neurodegenerative diseases: evidence from mouse disease models”, is available for download. The findings were published in PLoS One, the Journal of Alzheimer’s Disease, and most recently in the journal Human Molecular Genetics.
Related Links:
University of Eastern Finland
Latest Pathology News
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
- Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
- AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
- AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
- Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
- New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
- AI-Powered Tool to Transform Dermatopathology Workflow
- AI Tool Predicts Chemotherapy Response from Biopsy Slides
- Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
- World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
- Novel mcPCR Technology to Transform Testing of Clinical Samples
- Pathogen-Agnostic Testing Reveals Hidden Respiratory Threats in Negative Samples
- Molecular Imaging to Reduce Need for Melanoma Biopsies
- Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
- AI-Powered 3D Scanning System Speeds Cancer Screening
- Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
Lynch syndrome is a hereditary condition that increases risk for colorectal and endometrial cancers and often results in earlier-onset disease. Clinicians need better ways to stratify asymptomatic carriers... Read more
Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a progressive condition characterized by obstructed pulmonary blood flow and strain on the right heart, with half of patients dying within five years of diagnosis.... Read more
Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
Racial survival disparities in early-stage breast cancer remain a persistent clinical concern in the United States, with Black women experiencing higher mortality despite similar treatments.... Read more
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







